Amine compound or its pharmaceutically acceptable salt and its preparation and application

By extracting and isolating the amine compound pegaharoline A from camel wool, the problem of lack of effective non-small cell lung cancer treatment drugs in the prior art was solved, and the significant inhibitory effect on this cell type was achieved, and the development of Chinese medicinal materials was developed. New possibilities are provided.

CN115772092BActive Publication Date: 2024-11-08GUANGZHOU JIQING BIOMEDICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202111049811.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-09-08
Publication Date
2024-11-08
Estimated Expiration
2041-09-08

AI Technical Summary

Technical Problem

There is a lack of effective drugs for the treatment of non-small cell lung cancer in the prior art, and no amine compounds were found in the camel sac, which limits its application in anti-tumor treatment.

Method used

A novel amine compound pegaharoline A is extracted and isolated from camel sac, and its pharmaceutically acceptable salt is prepared by specific extraction and purification methods for the preparation of drugs for the prevention or treatment of tumors. The method includes 85% to 95% ethanol extraction, chloroform extraction, non-polar resin elution, silica gel column chromatography and gel Sephadex LH-20 separation, and finally purified by high performance liquid chromatography to obtain pegaharoline A.

Benefits of technology

pegaharoline A shows significant anti-tumor activity, can inhibit the proliferation, induce apoptosis, inhibit migration and invasion of non-small cell lung cancer cells, provide a new foundation for the development of anti-tumor drugs, and has the ability to dispel wind and dehumidify, relieve muscles and promote blood circulation. Effective, suitable for the treatment of symptoms such as rheumatoid arthritis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115772092B_ABST
    Figure CN115772092B_ABST
Patent Text Reader

Abstract

The present invention discloses an amine compound or a pharmaceutically acceptable salt thereof in the field of natural drug chemistry technology and its preparation and application. The molecular formula of the amine compound is C 12 H 17 N2O3, named pegaheroline A, has a chemical structure as shown in Formula I. This amine compound is discovered for the first time. This compound or its pharmaceutically acceptable salt has obvious anti-tumor activity and has a good inhibitory effect on tumor cells, especially on non-small cell lung cancer cells A549 and PC9. It has obvious proliferation inhibition, apoptosis induction, and inhibition of cell migration and invasion ability. This amine compound has the potential to prepare pharmaceutical preparations for preventing or treating tumors and related diseases, and provides a new material basis for the development of innovative anti-tumor drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of natural drug chemistry, and specifically relates to an amine compound or a pharmaceutically acceptable salt thereof, and preparation and application thereof. Background Art

[0002] Lung cancer is one of the most common malignant tumors in the world. With the growth of the global population and the increase of the aging population, the incidence of lung cancer has been increasing, becoming the tumor with the highest mortality rate. According to statistics released by the World Health Organization in 2015, there were about 1.8 million new cases of lung cancer in the world in 2012, accounting for 13% of all tumor types. In 2013, there were about 550,000 deaths from lung cancer in China, accounting for 1 / 3 of the global deaths from this type of cancer. In my country, the incidence and mortality of lung cancer in men ranked first among all malignant tumors, while the incidence and mortality of lung cancer in women ranked second and first. According to statistics from the National Cancer Center, there were about 730,000 cases of lung cancer in China in 2015, including about 510,000 males and about 220,000 females; in the same year, there were about 610,000 deaths from lung cancer in China, including about 430,000 males and about 180,000 females. The incidence and mortality of lung cancer increase with age, generally rising significantly after the age of 40, reaching a peak around the age of 75, and then declining.

[0003] Non-small cell lung cancer (NSCLC) is a common lung malignancy, which refers to a disease in which cells in the lung tissue grow out of control. This cell growth may cause metastasis, that is, invade adjacent tissues and penetrate outside the lungs. Non-small cell lung cancer accounts for about 80-85% of all lung cancers. It is a heterogeneous tumor that can be further divided into squamous cell carcinoma, adenocarcinoma and large cell carcinoma. The vast majority of non-small cell lung cancers originate from the bronchial mucosal epithelium. Most NSCLC patients are already in the advanced stage when diagnosed. NSCLC patients with locally advanced disease and good physical condition can achieve an 8-month disease-free survival (DFS) period through a series of chemotherapy, radiotherapy and / or surgical treatment, and the 5-year survival rate is less than 15%. Therefore, it is very necessary to find new and effective therapeutic drugs.

[0004] Peganum harmala L. is the dried mature seed of the plant Peganum harmala L. of the genus Peganum of the family Zygophyllaceae. Its seeds are triangular, kidney-shaped, brown, and are one of the common medicinal parts of the genus Peganum. It tastes spicy and bitter, is flat in nature, and is toxic. It enters the heart, liver, and lung meridians, and has the effects of promoting lung qi, relieving cough and asthma, removing rheumatism, and reducing swelling and toxins. The plant is widely distributed around the world, mainly distributed in Asia, Europe, North Africa and other places, and is mainly distributed in Xinjiang, Inner Mongolia, Shaanxi, Gansu, Ningxia and other regions in China. The plant contains ingredients such as alkaloids, steroids, flavonoids, anthraquinones, and amino acids, among which the seed part of the plant contains rich alkaloid components, mainly including two types of β-carboline and quinazoline. At the same time, its alkaloid part is the main active ingredient of the plant to exert its pharmacological effects. Some commercial preparations with camel thorn fruit as one of the raw materials also have corresponding therapeutic effects on the treatment of corresponding diseases. For example, the compound camel thorn fruit ointment with camel thorn fruit, henbane, and colchicum as the main raw materials has the effect of treating scabies, sciatica, rheumatoid arthritis and other diseases; the compound muniziqi granules with camel thorn fruit, chicory seed, celery root, chicory root, vanilla seed, black seed, fennel root bark, chamomile, licorice, lemongrass, basil seed, marshmallow seed, and anise fruit as the main ingredients have the effect of treating cholecystitis and hepatitis diseases; the snow lotus foot bath with camel thorn fruit, snow lotus, saffron, kawaweiqin, buyawuerke and other main ingredients can improve microcirculation and has a good effect on tinea pedis, athlete's foot, and foot sweat. The current research mainly focuses on the research of β-carboline alkaloids and quinazoline alkaloids, and no amine compounds have been found to be isolated from camel thorn fruit. Summary of the invention

[0005] In order to solve the deficiencies in the prior art, the object of the present invention is to provide an amine compound or a pharmaceutically acceptable salt thereof and its preparation and application. The specific technical scheme is as follows:

[0006] The first aspect of the present invention provides an amine compound and a pharmaceutically acceptable salt thereof, wherein the molecular formula of the amine compound is C 12 H 17 N2O3, named pegaheroline A, has a chemical structure as shown in Formula I:

[0007]

[0008] The second aspect of the present invention provides a method for preparing an amine compound, comprising the following steps:

[0009] (1) extracting the crushed dried camel thorn fruit with 85% to 95% ethanol, preferably 95% ethanol, to obtain a total extract;

[0010] (2) dispersing the obtained extract in water, adjusting the pH to 2-4, adding chloroform for extraction, discarding the organic layer, and obtaining the aqueous layer;

[0011] (3) adjusting the pH of the obtained aqueous layer to 7.5-9, adding chloroform for extraction, and retaining the chloroform layer to obtain the total alkaloids;

[0012] (4) loading the total alkaloids onto a non-polar resin and eluting with 30%, 50%, 75% and 95% ethanol / water systems in sequence to obtain 30%, 50%, 75% and 95% ethanol / water system elution fractions;

[0013] (5) The obtained 95% ethanol / water fraction was separated by silica gel column chromatography using chloroform / methanol as the mobile phase with a gradient elution ratio of 100:0 to 0:100, and the fractions were combined after TLC inspection to obtain 7 fractions Fr.AG;

[0014] (6) The Fr.F fraction was separated by silica gel column chromatography using methanol / water with a volume ratio of 10:90, 20:80, 30:70, 50:50, and 100:0 as the mobile phase, and then combined by TLC inspection to obtain five sub-fractions, Fr.F1-5;

[0015] (7) Fr.F5 was separated by Sephadex LH-20 gel and further purified by preparative HPLC to obtain the amine compound pegaheroline A.

[0016] Furthermore, the amount of 85% to 95% ethanol is 8 to 10 times the amount of the medicinal material of Camelia salsa, preferably 10 times;

[0017] The non-polar resin is D101 macroporous resin;

[0018] The mobile phase of the gel Sephadex LH-20 is chloroform / methanol in a volume ratio of 2:1;

[0019] The mobile phase of the preparative high performance liquid chromatography is methanol / water / ammonia water in a volume ratio of 70:30:0.01.

[0020] The third aspect of the present invention provides the use of the amine compound and / or its pharmaceutically acceptable salt, or the amine compound and / or its pharmaceutically acceptable salt prepared by the preparation method in the preparation of a drug for preventing or treating tumors.

[0021] Further, the tumor is lung cancer; preferably, the tumor is non-small cell lung cancer. More preferably, the tumor cell is non-small cell lung cancer cell A549 or PC9.

[0022] The fourth aspect of the present invention provides a pharmaceutical preparation for preventing or treating tumors, comprising the amine compound and / or a pharmaceutically acceptable salt thereof, or the amine compound and / or a pharmaceutically acceptable salt thereof prepared by the preparation method.

[0023] Further, the tumor is lung cancer; preferably, the tumor is non-small cell lung cancer. More preferably, the tumor cell is non-small cell lung cancer cell A549 or PC9.

[0024] Furthermore, the pharmaceutical preparation further comprises a therapeutically effective amount of at least one other therapeutic agent or a combination thereof;

[0025] Preferably, the other therapeutic agent or the combination thereof is selected from any substance or the combination thereof having anti-tumor activity.

[0026] Furthermore, the pharmaceutical preparation also includes pharmaceutically acceptable excipients.

[0027] Preferably, the pharmaceutically acceptable excipient is selected from one or more of starch, lactose, microcrystalline cellulose, dextrin, calcium phosphate, polyethylene glycol-4000, polyethylene glycol-6000, sodium carboxymethyl cellulose, hydroxypropyl cellulose or cross-linked polyvinylpyrrolidone.

[0028] Furthermore, the dosage form of the drug preparation includes tablets, capsules, pills or granules. These preparations are relatively convenient to take, can be taken alone or in combination with other medicines, and can be taken orally to quickly transport the drug properties to the diseased site through the blood for effective treatment.

[0029] The beneficial effects of the present invention are:

[0030] 1. The amine compounds provided by the present invention do not belong to the existing isolated alkaloid compounds, and are discovered for the first time. The compounds and pharmaceutically acceptable salts thereof have obvious anti-tumor activity and have a good inhibitory effect on tumor cells, especially on non-small cell lung cancer cells A549 and PC9. They have obvious proliferation inhibition, apoptosis induction, and inhibition of cell migration and invasion ability. The amine compounds have the potential to be used in the preparation of pharmaceutical preparations for the prevention or treatment of tumors and related diseases, and provide a new material basis for the development of innovative anti-tumor drugs, with potential and huge social and economic benefits. The compounds provided by the present invention can provide a material basis for the development of new anti-tumor drugs, are conducive to the further development of the medicinal value of the Chinese medicinal material Camel Pepper, and provide effective therapeutic small molecule drugs for non-small cell lung cancer, etc.

[0031] 2. The preparation method of the amine compounds provided by the present invention is simple, low-cost, low-pollution, and has good economic benefits as finished medicines. It is conducive to large-scale production under conditions of energy conservation and emission reduction, and has good industrialization prospects.

[0032] 3. The amine compounds of the present invention also have the effects of dispelling wind and dampness, relaxing muscles and activating blood circulation, and can be used for rheumatoid arthritis, traumatic injuries, swelling and pain due to congestion, postpartum paralysis, etc., and can be used to prevent or treat tumors while playing the role of treating other complications. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 is the chemical structural formula of the compound pegaharoline A;

[0034] Figure 2 is the molecular number of the compound pegaharoline A;

[0035] Figure 3 This is the high-resolution mass spectrum of the compound pegaharoline A;

[0036] Figure 4 is the UV spectrum of the compound pegaharoline A;

[0037] Figure 5 is the outer infrared spectrum of the compound pegaharoline A;

[0038] Figure 6 NMR of pegaharoline A 1 H spectrum;

[0039] Figure 7 NMR of pegaharoline A 13 C spectrum;

[0040] Figure 8 is the DEPT-135 nuclear magnetic resonance spectrum of the compound pegaharoline A;

[0041] Fig. 9 NMR of pegaharoline A 1 H- 1 H COSY spectrum;

[0042] Fig.10 is the NMR HSQC spectrum of the compound pegaharoline A;

[0043] Fig.11 is the HMBC NMR spectrum of the compound pegaharoline A;

[0044] Fig.12 is the nuclear magnetic resonance NOESY spectrum of the compound pegaharoline A;

[0045] Fig.13The effect of the compound pegaharoline A on the proliferation of non-small cell lung cancer cells A549 and PC9; A, the effect of the compound pegaharoline A on the proliferation of non-small cell lung cancer cells A549 at different action times; B, the effect of the compound pegaharoline A on the proliferation of non-small cell lung cancer cells PC9 at different action times;

[0046] Fig.14 Effect of pegaharoline A on apoptosis of non-small cell lung cancer A549 cells; A, Effect of pegaharoline A on apoptosis of non-small cell lung cancer A549 cells; B, apoptosis statistics;

[0047] Fig.15 Effects of pegaharoline A on the migration and invasion of non-small cell lung cancer A549 cells; A, Effects of pegaharoline A on the migration and invasion of non-small cell lung cancer A549 cells; B, Migration statistics; C, Invasion statistics;

[0048] Fig.16 Effect of pegaharoline A on clone formation of non-small cell lung cancer cell A549; A, Effect of pegaharoline A on clone formation of non-small cell lung cancer cell A549; B, Cloning statistics;

[0049] Fig.17 The effect of the compound pegaharoline A on the angiogenesis of non-small cell lung cancer A549 cells; A, the effect of the compound pegaharoline A on the angiogenesis of HUVEC cells; B, the statistics of blood vessel length; C, the statistics of blood vessel percentage; C, the statistics of blood vessel connection length. DETAILED DESCRIPTION

[0050] In order to understand the present invention more clearly, the present invention is further described with reference to the following examples and accompanying drawings. The examples are only used for explanation and are not intended to limit the present invention in any way. In the examples, each raw material reagent is commercially available, and the experimental methods without specifying specific conditions are conventional methods and conventional conditions well known in the art, or according to the conditions recommended by the instrument manufacturer.

[0051] Example 1

[0052] 30 kg of dried Peganum harmala medicinal materials were crushed and extracted with 95% ethanol (300 L) at room temperature to obtain 3.2 kg of extract. The obtained extract was dispersed in water (10 L), adjusted to pH 3 with 1% hydrochloric acid, and chloroform (5 L) was added. The organic layer was discarded after sufficient extraction. The remaining water layer was adjusted to pH 8 with 2% ammonia water, and then extracted with chloroform (5 L). The chloroform layer was retained to obtain the total alkaloids of Peganum harmala (969 g). The total alkali was chromatographed on a D101 macroporous resin column and eluted with ethanol / water as the mobile phase system to obtain 275 g, 288 g, 176 g and 97 g of the fractions eluted with 30%, 50%, 75% and 95% ethanol / water systems, respectively. The eluted 95% ethanol / water fraction was separated by silica gel column chromatography using chloroform / methanol as the mobile phase in a gradient elution ratio from 100:0 to 0:100, and merged according to TLC inspection to obtain 7 fractions (Fr.AG). The Fr.F (15.8 g) fraction was separated by silica gel column chromatography using methanol / water (10:90, 20:80, 30:70, 50:50, 100:0; v / v) as the mobile phase, and merged according to TLC inspection to obtain five sub-fractions Fr.F1-5. Fr.F5 (2.2 g) was separated by gel Sephadex LH-20 (chloroform / methanol; 2:1; v / v), and further purified by preparative HPLC (methanol / water / ammonia water; 70:30:0.01; v / v / v) to obtain the compound pegaheroline A, the compound structure is shown in Figure 1 The molecular number of the compound pegaheroline A is shown in Figure 2 shown.

[0053] The data of 2D NMR spectra and the binding relationships are shown in Table 1 .

[0054] Structural identification based on:

[0055] The structure of the compound pegaharoline A was inferred by analyzing high resolution mass spectrometry (HRESIMS), infrared spectroscopy (IR) and nuclear magnetic resonance spectroscopy (NMR).

[0056] Figure 3 This is the high-resolution mass spectrum of the compound pegaheroline A. Figure 4 is the UV spectrum of the compound pegaheroline A (dissolved in methanol), Figure 5 This is the infrared spectrum of the compound pegaheroline A (KBr pellet), Figure 6 NMR of pegaharoline A 1 H spectrum (600 MHz, dissolved in DMSO-d6), Figure 7 NMR of pegaharoline A 13C spectrum (150 MHz, dissolved in DMSO-d6), Figure 8 is the DEPT-135 nuclear magnetic resonance spectrum of the compound pegaheroline A (150 MHz, dissolved in DMSO-d6), Fig. 9 NMR of pegaharoline A 1 H- 1 H COSY spectrum (dissolved in DMSO-d6), Fig.10 is the NMR HSQC spectrum of the compound pegaharoline A (dissolved in DMSO-d6), Fig.11 is the HMBC NMR spectrum of the compound pegaharoline A (dissolved in DMSO-d6), Fig.12 This is the nuclear magnetic resonance NOESY spectrum of compound pegaharoline A (dissolved in DMSO-d6).

[0057] Molecular weight determined by high resolution mass spectrometry HRESIMS: m / z 237.1233 [M+H] + (Theoretical value: 237.1234), showing the molecular formula is C 12 H 17 N2O3.

[0058] The infrared spectroscopy showed that there was an amino group (3406 cm -1 ) and benzene ring (1616 and 1468 cm -1 ).

[0059] H NMR ( 1 HNMR) data and attribution, see Table 1. The data show: δ H The absorption peaks of 7.64 (1H, d, J = 9.0 Hz), 6.24 (1H, d, J = 2.4 Hz), and 6.14 (1H, dd, J = 9.0, 2.4 Hz) indicate that there is a benzene ring of the AMX system; δ H The absorption peaks of 3.32 (2H, t, J = 6.8 Hz) and 2.98 (2H, t, J = 6.8 Hz) indicate that there is a -CH2CH2- coupling fragment; δ H The absorption peak of 3.73 (3H, s) indicates that there is a methoxy group; δ H The absorption peak of 1.77 (3H, s) indicates that there is a methyl group; δ H The absorption peak of 7.89 (1H, t, J = 5.0 Hz) indicates an imino group; δ H The absorption peak at 7.34 (2H, br s) indicates an amino group.

[0060] According to the carbon nuclear magnetic resonance spectrum ( 13C NMR) data and attribution are shown in Table 1. The data show that there are 12 carbon signals: δ C 198.4and 169.3 show two carbonyl signals; δ C 163.8, 153.6, 133.3, 111.3, 103.6, 98.5 showed six benzene ring carbon signals; δ C 38.1and 34.9 show two methylene carbon signals; δ C 55.0 shows a methoxy carbon signal; δ C 22.6 shows a methyl carbon signal.

[0061] Table 1. NMR data of 1 (DMSO-d6, 600 MHz for 1 H,150MHz for 13 C,δinppm,Jin Hz)

[0062]

[0063] The present invention verifies the anti-tumor effect of compound pegaharoline A through Experimental Examples 1-5. In Experimental Examples 1-5, the culture medium for culturing cells is DMEM plus 10% FBS, and the compound pegaharoline A is denoted as PA in the accompanying drawings of the specification.

[0064] Experimental Example 1: The compound pegaheroline A can significantly inhibit the proliferation of non-small cell lung cancer cells A549 and PC9

[0065] 1. Non-small cell lung cancer cells A549 and PC9 were cultured at 5×10 3 Each well was inoculated into a 96-well cell culture plate, with a medium volume of 200 μl per well, and cultured in an incubator containing 5% carbon dioxide at 37°C for 24 h, and then starved overnight;

[0066] 2. Add compounds with different concentration gradients (100 μM, 50 μM, 25 μM, 12.5 μM, 6.25 μM, 3.125 μM) and culture for 24 h, 48 h, and 72 h respectively;

[0067] 3. Add 20 μl of MTT working solution to each well and continue to culture in a carbon dioxide incubator for 4 hours;

[0068] 4. Discard the supernatant in the culture plate, add 150 μl DMSO (dimethyl sulfoxide), shake for 10 minutes, select 490nm wavelength for detection on the microplate reader, and draw the cell growth curve. The results are as follows Fig.13 .

[0069] Fig.13 The results showed that different concentrations of the compound pegaheroline A could significantly inhibit the proliferation of non-small cell lung cancer cells A549 and PC9, and as the action time increased, the effect of the compound pegaheroline A in inhibiting the proliferation of non-small cell lung cancer cells became more significant.

[0070] Experimental Example 2: Compound pegaheroline A can promote apoptosis of non-small cell lung cancer cells A549

[0071] 1. Non-small cell lung cancer A549 cells were cultured at 5×10 5 Each well was inoculated into a 6-well cell culture plate, with a medium volume of 1 ml per well, cultured for 24 h, and then starved overnight;

[0072] 2. Add compounds with different concentration gradients (12.5 μM, 25 μM, 50 μM) and culture for 48 hours, and set up a non-drug group as a control group;

[0073] 3. First collect the supernatant into a centrifuge tube, then carefully digest the cell culture medium with EDTA-free trypsin and collect it into a centrifuge tube. Centrifuge at about 500g for 5 minutes to precipitate the cells;

[0074] 4. Wash the cells twice with pre-cooled PBS and collect the cells by centrifugation at 500g for 5 minutes;

[0075] 5. Add 100 μl pre-cooled 1× Annexin V Binding Buffer and resuspend the cells;

[0076] 6. Add 5 μl Annexin V-FITC and 5 μl PI, mix gently, and react at room temperature in the dark for 15 minutes;

[0077] 7. Add 400 μl of pre-cooled 1× AnnexinVBinding Buffer, mix gently, place the sample on ice and avoid light, and detect it by flow cytometry within 1 hour. Analyze the test results. Fig.14 .

[0078] Fig.14 Flow cytometric analysis showed that the compound pegaheroline A could significantly promote apoptosis of non-small cell lung cancer cells A549 as the concentration increased. ** P<0.01 compared with the control group.

[0079] Experimental Example 3: The compound pegaheroline A can significantly inhibit the migration and invasion of non-small cell lung cancer cells A549

[0080] 1. Inoculate 2×10 cells in the upper chamber of Transwell 5 Cells were added with compounds of different concentration gradients (12.5 μM, 25 μM, 50 μM) and cultured for 24 h, and a group without drug administration was set as the control group;

[0081] 2. Add 800ul of culture medium containing 10% FBS to the lower chamber;

[0082] 3. Wash three times with PBS and fix with 4% paraformaldehyde for 30 min;

[0083] 4. Wash with PBS three times and stain with 0.5% crystal violet for 1 hour;

[0084] 5. Carefully scrape off the upper layer of cells with a cotton swab and take photos under a microscope. Fig.15 .

[0085] Fig.15 Experiments showed that with the increase of the concentration, the compound pegaheroline A can significantly inhibit the migration and invasion of non-small cell lung cancer cells A549. ** P<0.01 compared with the control group.

[0086] Experimental Example 4: The compound pegaheroline A can significantly inhibit the in vitro cloning ability of non-small cell lung cancer cells A549

[0087] 1. Non-small cell lung cancer A549 cells were seeded at 1000 cells / well in a 6-well cell culture plate, with a medium volume of 1 ml per well, cultured for 10 days, and then starved overnight;

[0088] 2. Add compounds with different concentration gradients (12.5μM, 25μM, 50μM) for 24 hours, and set up a non-drug group as a control group;

[0089] 3. Wash with PBS three times and fix with 4% paraformaldehyde for 30 min;

[0090] 4. Wash three times with PBS and stain with 0.5% crystal violet for 1 hour;

[0091] 5. Wash with PBS 3 times and take photos under a microscope. Fig.16 .

[0092] Fig.16 The results showed that through cloning experiments, it was found that with the increase of the concentration, the compound pegaheroline A can significantly inhibit the clone formation of non-small cell lung cancer cells A549. ** P<0.01 compared with the control group.

[0093] Experimental Example 5: The compound pegaheroline A can significantly inhibit the angiogenesis ability of HUVEC

[0094] 1. First, spread Matrigel on a 24-well plate overnight;

[0095] 2. HUVEC cells were cultured at 5×10 4 Cells were inoculated into 24-well cell culture plates, and compounds with different concentration gradients (25 μM, 50 μM) were added and cultured for 6 h. A group without drug administration was set as a control group.

[0096] 3. Wash with PBS 3 times and take photos under microscope. Fig.17 .

[0097] Fig.17 It was shown that with the increase of the concentration, the compound pegaheroline A could significantly inhibit HUVEC angiogenesis. ** P<0.01 compared with the control group.

[0098] It will be appreciated by those skilled in the art that the use of the present invention is not limited to the above-mentioned specific applications. The present invention is not limited to its preferred embodiments with respect to the specific elements and / or features described or depicted herein. It should be understood that the present invention is not limited to the disclosed embodiment examples or each embodiment, and that many rearrangements, modifications and substitutions can be made without departing from the scope of the present invention as set forth and defined by the following claims.

Claims

1. Use of an amine compound and / or a pharmaceutically acceptable salt thereof in the preparation of a medicament for preventing or treating non-small cell lung cancer, characterized in that: The molecular formula of the amine compound is C 12 H 17 N2O3, named pegaheroline A, has a chemical structure as shown in Formula I:

2. The use according to claim 1, characterized in that: The preparation method of the amine compound comprises the following steps: (1) extracting the crushed dried camel thorn fruit with 85% to 95% ethanol to obtain an extract; (2) dispersing the obtained extract in water, adjusting the pH to 2-4, adding chloroform for extraction, discarding the organic layer, and obtaining the aqueous layer; (3) adjusting the pH of the obtained aqueous layer to 7.5-9, adding chloroform for extraction, and retaining the chloroform layer to obtain the total alkaloids; (4) loading the total alkaloids onto a non-polar resin and eluting with 30%, 50%, 75% and 95% ethanol / water systems in sequence to obtain 30%, 50%, 75% and 95% ethanol / water system elution fractions; (5) The obtained 95% ethanol / water fraction was separated by silica gel column chromatography using chloroform / methanol as the mobile phase with a gradient elution ratio of 100:0 to 0:100, and the fractions were combined after TLC inspection to obtain 7 fractions Fr.AG; (6) The Fr.F fraction was separated by silica gel column chromatography using methanol / water with a volume ratio of 10:90, 20:80, 30:70, 50:50, and 100:0 as the mobile phase, and then combined by TLC inspection to obtain five sub-fractions, Fr.F1-5; (7) Fr.F5 was separated by Sephadex LH-20 gel and further purified by preparative HPLC to obtain the amine compound pegaharoline A.

3. The use according to claim 2, characterized in that: The dosage of 85% to 95% ethanol is 8 to 10 times the dosage of camel pistachio; The non-polar resin is D101 macroporous resin; The mobile phase of the gel Sephadex LH-20 is chloroform / methanol in a volume ratio of 2:1; The mobile phase of the preparative high performance liquid chromatography is methanol / water / ammonia water in a volume ratio of 70:30:0.01.